# JOHNS HOPKINS UNIVERSITY: 2/2 Efficacy and Safety of Obinutuzumab in Connective Tissue Disease-Related Interstitial Lung Disease

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | JOHNS HOPKINS UNIVERSITY |
| Location | BALTIMORE, MD |
| Project | 2/2 Efficacy and Safety of Obinutuzumab in Connective Tissue Disease-Related Interstitial Lung Disease |
| Project number | 1U24HL183678-01A1 |
| Mechanism | U24 |
| Institute | National Heart Lung and Blood Institute |
| Award | $1,446,483 |
| Awarded | 2026-09-07 |
| Project period | 2026-09-03 to 2031-05-31 |
| UEI | FTMTDMBR29C7 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11451395). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.